FDA Overhauls 'Dear Doctor' Guidance On Drug Risks
By Jeff Overley (January 22, 2014, 4:14 PM EST) -- The U.S. Food and Drug Administration on Wednesday finalized guidance on how drugmakers should warn physicians of newly discovered risks, eliminating expectations for tracking the impact of "dear doctor" letters but maintaining that even nonprescribers should be alerted.
In the guidance, FDA officials delivered on a promise last year to remove a controversial provision that would have directed pharmaceutical firms to assess the impact of their letters on health care providers and patients. Instead, regulators softened the provision to merely suggest that assessments be performed for internal company use.
Separately, however, the agency continued to insist that updated warnings be sent...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!